Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Recommendation of “Moderate Buy” by Analysts

Posted by on Sep 14th, 2026

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Free Report) have received an average rating of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $9.1667.

A number of equities research analysts have commented on AQST shares. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Monday, August 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $11.00 price objective on shares of Aquestive Therapeutics in a report on Thursday.

Read Our Latest Stock Analysis on Aquestive Therapeutics

Insider Transactions at Aquestive Therapeutics

In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total value of $125,500.00. Following the transaction, the director directly owned 25,000 shares of the company’s stock, valued at approximately $125,500. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sherry Korczynski sold 8,750 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $5.22, for a total value of $45,675.00. Following the completion of the transaction, the insider directly owned 235,689 shares in the company, valued at $1,230,296.58. The trade was a 3.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in AQST. AQR Capital Management LLC grew its position in Aquestive Therapeutics by 12.2% during the first quarter. AQR Capital Management LLC now owns 129,019 shares of the company’s stock valued at $374,000 after buying an additional 14,025 shares during the period. Geode Capital Management LLC raised its position in Aquestive Therapeutics by 16.2% in the second quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company’s stock worth $6,545,000 after acquiring an additional 276,295 shares during the period. Creative Planning boosted its stake in shares of Aquestive Therapeutics by 15.3% during the 2nd quarter. Creative Planning now owns 98,751 shares of the company’s stock worth $327,000 after acquiring an additional 13,130 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Aquestive Therapeutics by 46.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 435,972 shares of the company’s stock worth $1,443,000 after acquiring an additional 137,956 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of Aquestive Therapeutics by 35.0% during the 2nd quarter. Rhumbline Advisers now owns 140,872 shares of the company’s stock worth $466,000 after acquiring an additional 36,509 shares during the last quarter. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Price Performance

Shares of NASDAQ AQST opened at $4.78 on Monday. The firm’s 50-day moving average price is $4.39 and its 200-day moving average price is $4.26. Aquestive Therapeutics has a 52-week low of $2.93 and a 52-week high of $7.55. The company has a market cap of $599.94 million, a PE ratio of -7.35 and a beta of 1.48.

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The firm had revenue of $13.82 million for the quarter, compared to analysts’ expectations of $11.42 million. As a group, equities research analysts anticipate that Aquestive Therapeutics will post -0.5 EPS for the current fiscal year.

About Aquestive Therapeutics

(Get Free Report)

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines delivered through its PharmFilm technology. The company’s dissolvable oral-film platform is designed to provide alternatives to conventional tablets, capsules and injectable therapies, with potential benefits for patients who have difficulty swallowing or require rapid, convenient administration.

Aquestive’s commercial products include Exservan, an oral film formulation of riluzole for people with amyotrophic lateral sclerosis; Libervant, a buccal film formulation of diazepam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity; and Sympazan, an oral film formulation of clonazepam for the treatment of seizures associated with Lennox-Gastaut syndrome.

Featured Stories

Analyst Recommendations for Aquestive Therapeutics (NASDAQ:AQST)

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.